EUCTR2015-003118-26-IT招募中1 期
Perioperative RAMucirumab in combination with FLOT versus FLOT alone for reSEctable eSophagogastric adenocarcinoma RAMSES - a phase II/III trial of the AIO and GOIM - RAMSES/FLOT7
INSTITUTE OF CLINICAL CANCER RESEARCH (IKF) KRANKENHAUS NORDWEST GGMBH0 个研究点目标入组 180 人开始时间: 2021年1月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Histologically confirmed, resectable adenocarcinoma of the gastroesophageal junction (AEG/GEJ-type II-III) or the stomach (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications:
- •a.Medical and technical operability, according to the techniques described in Chapter 12 Surgical TherapySurgical Therapy that are subtotal, total or transhiatal extended gastrectomy (patients planned to receive transthoracic esophagectomy are not eligible for the study)
- •b.Participating sites in PETRARCA study: Negative HER-2 detection (score IHC HER-2 0 or IHC HER-2 1+ ); IHC HER-2 2+ and negative by FISH, SISH or CISH
- •2.No preceding cytotoxic or targeted therapy
- •3.No prior partial or complete tumor resection
- •4.Female and male patients = 18 and = 70 years. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of ramucirumab treatment (Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start
- •5.ECOG = 1
- •6.Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs). Exclusion of the infiltration of any adjacent organs or structures by CT or MRI
- •7.Laparoscopic exclusion of peritoneal carcinomatosis in case of ascites, peritoneal masses, or if otherwise suspected clinically.
- •8.Adequate hematological, hepatic and renal function parameters:
- •a.Leukocytes = 3000/mm³, platelets = 100,000/mm³, neutrophil count (ANC) =1000/µL, hemoglobin =9 g/dL (5.58 mmol/L),
- •b.Adequate coagulation function as defined by International Normalized Ratio (INR) = 1.5, and a partial thromboplastin time (PTT) = 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin/ phenprocoumon must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to randomization.
- •c.Serum creatinine = 1.5 x upper limit of normal
- •d.Urinary protein =1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is =2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).
- •e.Bilirubin = 1.5 x upper limit of normal, AST and ALT = 3.0 x upper limit of normal, alkaline phosphatase = 6 x upper limit of normal
- •9.Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •1.Known hypersensitivity against ramucirumab, 5-FU, leucovorin, oxaliplatin, or docetaxel
- •2.Other known contraindications against ramucirumab, 5-FU, leucovorin, oxaliplatin, or docetaxel
- •3.Patients with esophageal cancer and those with adenocarcinoma of GEJ type I and all patients who are planned to have transthoracic esophagectomy.
- •4.Clinically significant active coronary heart disease, clinically active cardiomyopathy or congestive heart failure, peripheral artery occlusive disease (PAOD, German pAVK), or any history of aortic aneurysm
- •5.Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina.
- •6.Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management.
- •7.Clinically significant valvular defect
- •8.Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix
- •9.Criteria of unresectability, e.g.:
- •Radiologically documented evidence of major blood vessel invasion or encasement by cancer.
- •Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastases!)
- •10.Known brain metastases
- •11.Other severe internal disease or acute infection
- •12.Peripheral polyneuropathy = NCI Grade II
- •13.Chronic inflammatory bowel disease
- •14.Grade 3-4 GI bleeding within 3 months prior to enrollment.
- •15.History of gastric perforation or fistulae in past 6 months
- •16.Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment.
- •17.The patient has undergone major surgery within 28 days prior to enrollment except staging laparoscopy.
- •18.Receiving chronic antiplatelet therapy, including aspirin (Once-daily aspirin use (maximum dose 325 mg/day) is permitted), nonsteroidal anti-inflammatory drugs (including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents.
- •19.History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered significant”) during the 3 months prior to randomization.
- •20.Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or ascites.
- •21.On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study
- •22.Subject pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment.
- •23.Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)
- •24.Any other concurrent antineoplastic treatment including irradiation
- •25. Current chronic alcohol, nicotine or drug abuse or history of chronic alcohol abuse during last 12 months. Nicotine abuse is defined as = 25 pack-years (Willigendael et al., 2004).
研究者
相似试验
进行中（未招募）
1 期
Comparison of a standard chemotherapy with additional medication (Ramucirumab) in one group for patients with operable gastric and esophagogastric cancerEUCTR2015-003118-26-DEInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest180
已完成
2 期
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)Gastroesophageal Junction CancerStomach CancerNCT02661971Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest180
进行中（未招募）
不适用
Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluation of safety and efficacy - RevliRitntreated chronic lymphocytic leukaemia (B-CLL)MedDRA version: 9.1Level: LLTClassification code 10003946Term: B-Lymphocytic, CLL (Kiel Classification)EUCTR2008-001430-27-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL)EUCTR2011-004912-43-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) - R-FCM in CPatients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treatedEUCTR2005-001569-33-ESDept. Hematology, Hospital Clinic60